 Harpoon Therapeutics, Inc. HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Dr. Bailes is a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy, and for nearly two decades, served in various executive leadership capacities for ASCO. 